China SXT Pharmaceuticals (SXTC) Enterprise Value (2018 - 2025)

China SXT Pharmaceuticals' Enterprise Value history runs 8 years deep, the most recent figure standing at -$21.2 million for Q3 2025.

• In Q3 2025, Enterprise Value fell 14.5% year-over-year to -$21.2 million; the TTM figure through Sep 2025 stood at -$21.2 million (down 14.5% YoY), while the FY2025 annual figure was -$18.1 million, down 50.11% from the prior year.
• Enterprise Value was -$21.2 million for Q3 2025 at China SXT Pharmaceuticals, down from -$18.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$3.0 million in Q3 2022 to a low of -$31.3 billion in Q3 2021.
• Historically, Enterprise Value has averaged -$3.1 billion across 5 years, with a median of -$16.5 million in 2022.
• The sharpest annual moves came in 2021 and 2022: Enterprise Value plunged 302416.82% in 2021, then surged 99.99% in 2022.
• A 5-year view of Enterprise Value shows it stood at -$31.3 billion in 2021, then soared by 99.99% to -$3.0 million in 2022, then plunged by 284.6% to -$11.5 million in 2023, then slumped by 61.47% to -$18.5 million in 2024, then declined by 14.5% to -$21.2 million in 2025.
• The last three Enterprise Value figures came in at -$21.2 million (Q3 2025), -$18.1 million (Q1 2025), and -$18.5 million (Q3 2024), per Business Quant data.